Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07CAQ
|
||||
Former ID |
DIB001396
|
||||
Drug Name |
SAFINGOL
|
||||
Synonyms |
Kynac; Kynacyte; SPC-100270; Safingol < Rec INN; L-threo-Dihydrosphingosine; SPC-100271 (HCl); (2S,3S)-2-Aminooctadecane-1,3-diol
|
||||
Drug Type |
Small molecular drug
|
||||
Structure |
Download2D MOL |
||||
Formula |
C18H40NO2+
|
||||
Canonical SMILES |
CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO
|
||||
InChI |
1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3/t17-,18-/m0/s1
|
||||
InChIKey |
OTKJDMGTUTTYMP-ROUUACIJSA-N
|
||||
CAS Number |
CAS 15639-50-6
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Protein kinase C | Target Info | Inhibitor | [530494] | |
References | |||||
Ref 521599 | ClinicalTrials.gov (NCT00084812) Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health. | ||||
Ref 531343 | A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2484-92. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.